Key clinical point: Lenalidomide appears to improve outcomes for patients with diffuse large B-cell lymphoma (DLBCL) when added to CHOP chemotherapy.
Major finding: Progression-free survival, the primary endpoint, was 34% better with R2-CHOP, compared with R-CHOP.
Study details: A randomized, phase 2 trial of 349 patients with DLBCL regardless of cell of origin.
Disclosures: The ECOG-ACRIN 1412 trial was supported by the National Cancer Institute and by Celgene. Dr. Nowakowski reported consulting/advising for and research funding from Celgene and others. Dr. Shipp reported consulting/advising for Bristol-Myers Squibb, honoraria from BMS and AstraZeneca, and institutional research funding from BMS and Bayer.
Nowakowski GS et al. 15-ICML, Abstract 006.